XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Patent and Technology License Agreements (Details) - USD ($)
9 Months Ended 12 Months Ended
Oct. 06, 2020
Jun. 30, 2024
Jun. 30, 2023
Sep. 30, 2021
Patent and Technology License Agreement – Mino-Lok [Member]        
Patent and Technology License Agreements [Line Items]        
Fee expense (in Dollars)   $ 90,000 $ 90,000  
Annual minimum royalty payment (in Dollars)   100,000    
Increasing annual royalties (in Dollars)   25,000    
Payable amount to NAT (in Dollars)   $ 1,100,000    
Patent and Technology License Agreement – Mino-Lok [Member] | Minimum [Member]        
Patent and Technology License Agreements [Line Items]        
Royalty rate   10.00%    
Patent and Technology License Agreement – Mino-Lok [Member] | Maximum [Member]        
Patent and Technology License Agreements [Line Items]        
Royalty rate   15.00%    
Increasing annual royalties (in Dollars)   $ 150,000    
Patent and Technology License Agreement – Mino-Lok [Member] | Royalties [Member] | Minimum [Member]        
Patent and Technology License Agreements [Line Items]        
Royalty rate   2.00%    
Patent and Technology License Agreement – Mino-Lok [Member] | Royalties [Member] | Maximum [Member]        
Patent and Technology License Agreements [Line Items]        
Royalty rate   7.00%    
License Agreement Eterna [Member]        
Patent and Technology License Agreements [Line Items]        
Obligated pay amount (in Dollars)   $ 51,000,000    
Revenue percentage   50.00%    
License Agreement Eterna [Member] | NoveCite [Member]        
Patent and Technology License Agreements [Line Items]        
Minority equity interest 25.00%      
License Agreement Eterna [Member] | Minimum [Member]        
Patent and Technology License Agreements [Line Items]        
Royalty rate   4.00%    
License Agreement Eterna [Member] | Royalties [Member] | Maximum [Member]        
Patent and Technology License Agreements [Line Items]        
Royalty rate   8.00%    
License Agreement with Eisai [Member]        
Patent and Technology License Agreements [Line Items]        
Upfront payment (in Dollars)   $ 40,000,000    
Commercial sales milestones (in Dollars)   $ 300,000,000    
Net sales percentage   50.00%    
Paying an extension fee (in Dollars)   $ 10,000,000    
License Agreement with Eisai [Member] | License Agreement [Member]        
Patent and Technology License Agreements [Line Items]        
License agreement development, description   Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and an aggregate of up to $22 million related to the achievement of net product sales thresholds. Citius Oncology was required to reimburse Eisai for up to $2.65 million of its costs to complete the Phase 3 pivotal clinical trial for LYMPHIR for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a Biologics License Application (“BLA”) for LYMPHIR.    
License Agreement with Eisai [Member] | Minimum [Member]        
Patent and Technology License Agreements [Line Items]        
Royalty rate   10.00%    
License Agreement with Eisai [Member] | Maximum [Member]        
Patent and Technology License Agreements [Line Items]        
Royalty rate   15.00%    
Development milestone payments (in Dollars)   $ 70,000,000    
License Agreement with Eisai [Member] | Dr. Reddy’s Laboratories, Ltd [Member]        
Patent and Technology License Agreements [Line Items]        
Development milestone payments (in Dollars)   $ 40,000,000    
License Agreement with Eisai [Member] | Royalties [Member] | Minimum [Member]        
Patent and Technology License Agreements [Line Items]        
Royalty rate   10.00%    
License Agreement with Eisai [Member] | Royalties [Member] | Maximum [Member]        
Patent and Technology License Agreements [Line Items]        
Royalty rate   15.00%    
NoveCite [Member] | License Agreement Eterna [Member]        
Patent and Technology License Agreements [Line Items]        
Research and development expense (in Dollars)       $ 5,000,000
Percentage of ownership additional shares 25.00%      
License Agreement [Member] | License Agreement Eterna [Member]        
Patent and Technology License Agreements [Line Items]        
Outstanding equity 75.00%